Email
The Food and Drug Administration is expected to make a historic decision by June 7: whether to approve a treatment for mild cognitive decline and early-stage dementia caused by Alzheimer’s.
The FDA hasn’t approved an Alzheimer’s drug since 2003, and there are still no approved treatments that target the cause, only that help manage the symptoms. This would be the first approved drug to target the brain function deterioration caused by the disease.
The treatment, produced by Cambridge-based Biogen and Tokyo’s Eisai Co., is called aducanumab and works by binding to the plaques between neurons and causing an immune response that removes them.